Articles by Gilles Boschetti

Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study

Roblin, Xavier; Boschetti, Gilles; Duru, Gérard; More

Inflammatory Bowel Diseases. 23(11):2048-2053, November 2017.

Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease

Roblin, Xavier; Duru, Gerard; Williet, Nicolas; More

Inflammatory Bowel Diseases. 23(1):126-132, January 2017.

Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years

Boschetti, Gilles; Nancey, Stephane; Daniel, Fady; More

Inflammatory Bowel Diseases. 22(12):2924-2932, December 2016.

Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohn's Disease

Boschetti, Gilles; Garnero, Patrick; Moussata, Driffa; More

Inflammatory Bowel Diseases. 21(2):331-336, February 2015.

Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases

Nancey, Stephane; Boschetti, Gilles; Moussata, Driffa; More

Inflammatory Bowel Diseases. 19(5):1043-1052, April 2013.

Human Herpesvirus 8-Associated Colorectal Kaposi's Sarcoma Occurring in a Drug-induced Immunocompromised Patient with Refractory Ulcerative Colitis: Report of a New Case and...

Pioche, Mathieu; Boschetti, Gilles; Cotte, Eddy; More

Inflammatory Bowel Diseases. 19(2):E12-E15, February 2013.